Josep M. Llovet

Josep M. Llovet, MD, PhD is Professor of Medicine at the Icahn School of Medicine at Mount Sinai and one of the most influential figures in hepatocellular carcinoma (HCC) research worldwide. He led the landmark SHARP trial—the phase III study that established sorafenib as the first systemic therapy to prolong survival in advanced HCC—transforming a disease with no prior effective systemic options and defining the modern era of HCC medical oncology. Dr. Llovet co-developed and continually refined the Barcelona Clinic Liver Cancer (BCLC) staging and treatment allocation system, which has become the globally adopted framework for HCC clinical management and trial design. His laboratory has systematically characterized HCC molecular subclasses, identifying Wnt/β-catenin activation, MYC amplification, and specific immune microenvironment subtypes as determinants of prognosis and therapeutic sensitivity. More recently, he has been a principal investigator and scientific leader for studies of atezolizumab plus bevacizumab and other immunotherapy-based combinations that have reshaped first-line HCC treatment. Dr. Llovet has published over 400 peer-reviewed articles with an h-index exceeding 110 and has received the AASLD Distinguished Scientific Achievement Award and EASL Recognition Award, among numerous honors.